Basit öğe kaydını göster

Primary central nervous system lymphoma: The role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy

dc.contributor.authorPANAGEAS, Katherine S.
dc.contributor.authorEkenel, MELTEM
dc.contributor.authorIWAMOTO, Fabio M.
dc.contributor.authorBEN-PORAT, Leah S.
dc.contributor.authorYAHALOM, Joachim
dc.contributor.authorDEANGELIS, Lisa M.
dc.contributor.authorABREY, Lauren E.
dc.date.accessioned2021-03-06T21:06:41Z
dc.date.available2021-03-06T21:06:41Z
dc.date.issued2008
dc.identifier.citationEkenel M., IWAMOTO F. M. , BEN-PORAT L. S. , PANAGEAS K. S. , YAHALOM J., DEANGELIS L. M. , ABREY L. E. , "Primary central nervous system lymphoma: The role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy", CANCER, cilt.113, ss.1025-1031, 2008
dc.identifier.issn0008-543X
dc.identifier.otherav_fd369173-5ab8-4644-9445-3b691f6e1c49
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/165666
dc.identifier.urihttps://doi.org/10.1002/cncr.23670
dc.description.abstractBACKGROUND. The most effective treatment for a new diagnosis of primary central nervous system lymphoma is high-close methotrexate (MTX)-based chemotherapy followed by whole-brain radiation therapy (WBRT). However, this combined modality treatment carries an increased risk of delayed neurotoxicity. For patients who achieve a complete response (CR) after induction that uses high-dose MTX-based chemotherapy, it is not clear if consolidation treatment is necessary. Therefore, a retrospective study was conducted to assess the impact of consolidation treatment after a CR to initial induction chemotherapy on disease control and survival.
dc.language.isoeng
dc.subjectSağlık Bilimleri
dc.subjectOnkoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titlePrimary central nervous system lymphoma: The role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy
dc.typeMakale
dc.relation.journalCANCER
dc.contributor.departmentMemorial Sloan Kettering Cancer Center , ,
dc.identifier.volume113
dc.identifier.issue5
dc.identifier.startpage1025
dc.identifier.endpage1031
dc.contributor.firstauthorID88909


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster